Johnson & Johnson (NYSE: JNJ) announced late-stage results for its COVID-19 vaccine in late January. The immediate focus was on the vaccine’s efficacy, which was markedly lower than efficacy levels reported by Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) for their COVID-19 vaccines.
In this Motley Fool Live video recorded on Feb. 1, 2021, Motley Fool contributors Keith Speights and Danny Vena discuss one reason why you can’t really compare J&J’s results with the results reported by Pfizer and Moderna.
